13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship

Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship

Pain is one of the most common presenting complaints encountered in ambulatory community practice, institutional hospital care, and long-term care settings across Canada. Effective pain management requires a precise mechanistic understanding of pain pathways, the systematic implementation of multimodal analgesia, and rigorous opioid stewardship. Pharmacists play a pivotal clinical role in selecting non-opioid foundations, calculating safe opioid rotations, preventing medication-induced organ toxicities, and co-dispensing harm reduction resources in accordance with national guidelines.

---

Neurobiological Classification of Pain Mechanisms

Appropriate analgesic selection begins with identifying the underlying neurobiological mechanism driving the patient's pain experience. Rational pharmacotherapy targets the specific pathophysiological pathways involved:

                           NEUROBIOLOGICAL PAIN TAXONOMY
                                         │
         ┌───────────────────────────────┼───────────────────────────────┐
         ▼                               ▼                               ▼
    NOCICEPTIVE                     NEUROPATHIC                     NOCIPLASTIC
• Somatic (skin, bone, muscle)   • Direct neural lesion/injury   • Central sensitization
• Visceral (internal organs)     • Burning, shooting, lancinating• Altered nociceptive processing
• Responsive to Acetaminophen,   • Responsive to Gabapentinoids, • Fibromyalgia, IBS, tension HA
  NSAIDs, and Opioids              SNRIs, and TCAs               • Responsive to SNRIs, TCAs,
                                                                   exercise; OPIOIDS INEFFECTIVE

1. Nociceptive Pain

Nociceptive pain arises from actual or threatened damage to non-neural tissue and is mediated by the activation of peripheral nociceptors (A-delta and C fibers) in response to noxious thermal, mechanical, or chemical stimuli.

• Somatic Pain: Involves cutaneous tissue, musculoskeletal structures, joints, bones, and ligaments. It is classically well-localized, aching, throbbing, or sharp (e.g., acute post-surgical incision pain, osteoarthritic knee pain, bone fractures).
• Visceral Pain: Arises from internal organs and smooth muscle viscera (e.g., bowel distension, hepatic capsule stretch, pancreatitis). It is typically poorly localized, diffuse, cramping, deep, or colicky, and is frequently accompanied by referred pain, autonomic symptoms (nausea, diaphoresis, pallor), and muscular guarding.
• Therapeutic Approach: Highly responsive to primary anti-inflammatory and analgesic medications, including acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and opioid receptor agonists.

2. Neuropathic Pain

Neuropathic pain is defined by the International Association for the Study of Pain (IASP) as pain caused by a primary lesion or disease of the somatosensory nervous system.

• Peripheral Neuropathic Pain: Post-herpetic neuralgia (PHN), painful diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy, radiculopathy.
• Central Neuropathic Pain: Post-stroke central pain, spinal cord injury pain, multiple sclerosis-associated neuropathic pain.
• Clinical Presentation: Described as burning, shooting, electric shock-like, lancinating, or freezing. Physical examination frequently reveals allodynia (pain elicited by an innocuous stimulus such as light touch or clothing) and hyperalgesia (exaggerated pain response to a mildly noxious stimulus).
• Therapeutic Approach: Poorly responsive to conventional acetaminophen, NSAIDs, and pure opioids. Canadian Neuropathic Pain Guidelines establish first-line agents as gabapentinoids (gabapentin, pregabalin), SNRIs (duloxetine), and tricyclic antidepressants (amitriptyline, nortriptyline).

3. Nociplastic Pain

Nociplastic pain describes pain that arises from altered nociception despite no clear evidence of actual or threatened tissue damage activating peripheral nociceptors, nor evidence for disease or lesion of the somatosensory system.

• Clinical Examples: Fibromyalgia, irritable bowel syndrome (IBS), chronic tension-type headaches, temporomandibular joint disorder (TMD).
• Mechanism: Characterized by central sensitization, neuroinflammation, deficient descending inhibitory noradrenergic/serotonergic pain pathways, and diffuse sensory hyper-responsiveness.
• Therapeutic Approach: Opioids and NSAIDs are ineffective and contraindicated for routine chronic use due to lack of efficacy, risk of opioid-induced hyperalgesia (OIH), and dependence. Treatment emphasizes non-pharmacologic interventions (aerobic exercise, cognitive behavioral therapy) combined with central neurochemical modulators such as SNRIs (duloxetine) or low-dose tricyclic antidepressants.

---

The Analgesic Ladder & Multimodal Analgesia

Originally introduced by the World Health Organization (WHO) for cancer pain management, the analgesic ladder has evolved into a bidirectional, non-linear multimodal framework in modern clinical practice:

                       MODERN MULTIMODAL ANALGESIA FRAMEWORK

       PERIPHERAL TISSUE                  SPINAL DORSAL HORN                     CEREBRAL CORTEX
┌──────────────────────────────┐    ┌──────────────────────────────┐    ┌──────────────────────────────┐
│ • Acetaminophen (central)    │    │ • Opioids (mu-receptors)     │    │ • Opioids (mu-receptors)     │
│ • NSAIDs (COX-1/COX-2)       │───►│ • Gabapentinoids (Ca2+ block)│───►│ • Acetaminophen (cannabinoid)│
│ • Local anesthetics (Na+)    │    │ • SNRIs / TCAs (NE/5-HT)     │    │ • Non-pharm (CBT, ice/heat)  │
│ • Topical capsaicin / NSAID  │    │ • Ketamine (NMDA antagonist) │    │ • Central alpha-2 agonists   │
└──────────────────────────────┘    └──────────────────────────────┘    └──────────────────────────────┘

• Principle of Multimodal Analgesia: The concurrent administration of two or more analgesic agents with distinct mechanisms of action that act synergistically at different levels of the central and peripheral nervous system. This approach produces superior pain control while reducing individual drug doses, thereby minimizing opioid requirements and mitigating adverse effect profiles (an "opioid-sparing effect").

---

Non-Opioid Foundations: Acetaminophen & NSAIDs

1. Acetaminophen (Paracetamol)

• Mechanism of Action: Acts primarily centrally by inhibiting central prostaglandin synthesis through peroxidase-dependent inhibition of cyclooxygenase (COX) enzymes, activation of descending serotonergic inhibitory pathways, and active cannabinoid/TRPV1 metabolite interaction (AM404). It possesses analgesic and antipyretic properties but lacks clinically meaningful peripheral anti-inflammatory or antiplatelet activity.
• Dosing Parameters:
  • Healthy Adults: 325 mg to 650 mg PO every 4 to 6 hours, or 1000 mg PO every 6 hours PRN. Maximum daily dose is 4000 mg (4 g/day) from all prescription and over-the-counter sources combined.
  • High-Risk Populations: In chronic alcohol consumption (≥ 3 drinks daily), chronic liver disease (cirrhosis, chronic hepatitis), severe frailty, advanced age, or severe malnutrition/low body weight (< 50 kg), the maximum safe daily dose is reduced to 2000 mg to 3000 mg (2 to 3 g/day) to prevent hepatotoxicity.
• Pathophysiology of Hepatotoxicity:
  • At therapeutic doses, 85% to 90% of acetaminophen undergoes Phase II hepatic glucuronidation and sulfation into non-toxic metabolites. Approximately 5% to 10% is metabolized by cytochrome P450 CYP2E1 into the highly reactive, electrophilic, hepatotoxic intermediate N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is immediately detoxified by conjugation with endogenous hepatic glutathione into non-toxic cysteine and mercapturic acid conjugates.
  • In overdose or chronic glutathione depletion, the sulfation and glucuronidation pathways saturate. Massive shunting through CYP2E1 rapidly depletes hepatic glutathione stores. Once glutathione drops below ~30% of normal, unbound NAPQI binds covalently to intracellular hepatocyte proteins and mitochondrial membranes, triggering oxidative necrosis and centrilobular hepatic necrosis.
• Toxicity Management:
  • Rumack-Matthew Nomogram: Applies strictly to single, acute, non-enteric-coated ingestions presenting within 4 to 24 hours post-ingestion. Serum acetaminophen concentrations drawn prior to 4 hours post-ingestion cannot be interpreted due to incomplete gastrointestinal absorption.
  • Antidote: N-acetylcysteine (NAC) acts as a glutathione precursor, directly conjugates with NAPQI, and provides antioxidant cytoprotection. Administered IV (Acetadote) or orally. NAC is nearly 100% hepatoprotective if administered within 8 hours of acute ingestion, but must still be initiated if the patient presents later with toxic levels or evidence of transaminitis.

2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs produce analgesia, antipyresis, and anti-inflammatory activity through the inhibition of cyclooxygenase enzymes (COX-1 and COX-2), thereby blocking the conversion of arachidonic acid into pro-inflammatory prostaglandins, prostacyclin, and thromboxane A2.

• Non-Selective NSAIDs: Ibuprofen, naproxen, indomethacin, ketorolac, diclofenac (variable selectivity).
• COX-2 Selective NSAIDs: Celecoxib (selectively inhibits inducible COX-2 at sites of inflammation while sparing constitutive COX-1 in the gastric mucosa and platelets at standard therapeutic doses).

• Ketorolac Duration Cap: Systemic ketorolac (IV, IM, oral) is indicated strictly for short-term management of moderate to severe acute pain (e.g., post-operative). It is limited to a maximum duration of 5 consecutive days due to high rates of severe peptic ulceration, gastrointestinal hemorrhage, and acute renal failure with prolonged exposure.
• Topical NSAIDs: Topical diclofenac (Pennsaid 1.5% or 2% solution, Voltaren Emulgel 1.16% or 2.32%) is recommended as first-line therapy for localized osteoarthritis of the knee or hands in older adults. It delivers effective local concentrations into articular tissue while achieving systemic bioavailability of only 5% to 10% of equivalent oral dosing, dramatically reducing systemic GI, renal, and CV adverse events.

---

Opioid Analgesics: Equianalgesic Conversions & MME Calculations

When managing severe acute pain or rotating opioids in chronic pain, pharmacists must master equianalgesic conversions and calculate the total daily Oral Morphine Milligram Equivalent (MME).

Standard Canadian Equianalgesic Conversion Ratios

                  CANADIAN ORAL EQUIANALGESIC BASELINE VALUES

   Oral Morphine    Oral Oxycodone    Oral Hydromorphone    Oral Codeine
     30 mg       ≈      20 mg       ≈        6 mg        ≈     200 mg
  (Factor: 1.0)     (Factor: 1.5)        (Factor: 5.0)     (Factor: 0.15)

Step-by-Step Opioid Rotation Calculation Protocol

When rotating a patient from one opioid to another due to intolerable adverse effects or inadequate analgesia, clinicians must systematically execute a 4-step protocol:

1. Calculate the Total 24-Hour Baseline Dose: Sum all regular round-the-clock doses plus all PRN breakthrough doses consumed over the preceding 24 hours.
2. Convert to Oral Morphine Milligram Equivalents (MME): Multiply the 24-hour dose of the current drug by its specific MME conversion factor.
3. Apply a 25% to 50% Dose Reduction for Incomplete Cross-Tolerance:
   • Because mu-opioid receptors possess structural micro-heterogeneity and patients exhibit incomplete cross-tolerance to a newly introduced opioid, directly administering 100% of the calculated equianalgesic dose can precipitate fatal respiratory depression.
   • Standard Clinical Practice: Reduce the calculated equianalgesic daily dose by 25% to 50% (use a 50% reduction if the patient is elderly, frail, or being rotated to methadone; use 25% to 30% if pain is severe and uncontrolled).
4. Convert to the Target Opioid and Divide into Regimen: Divide the reduced total daily dose into the appropriate administration frequency for the chosen formulation (e.g., Q12H for sustained-release, Q4H for immediate-release). Provide a breakthrough dose equal to 10% to 15% of the total 24-hour baseline dose, available every 2 to 4 hours PRN.

---

Canadian Guideline for Opioids in Chronic Non-Cancer Pain

The Canadian Guideline for Opioids for Chronic Non-Cancer Pain outlines evidence-based stewardship recommendations to curb the harms of long-term opioid therapy:

• First-Line Priority for Non-Opioids: Optimize non-pharmacologic therapy (exercise, CBT) and non-opioid pharmacotherapy (acetaminophen, NSAIDs, SNRIs, gabapentinoids) before considering any opioid trial.
• Watchful Dose Threshold (50 mg MME/day): When initiating or titrating opioids, clinicians should strongly consider pausing and reassessing response at 50 mg MME/day. Observational data demonstrate that the risk of fatal and non-fatal overdose doubles as doses rise between 50 and 90 mg MME/day.
• Upper Stewardship Ceiling (90 mg MME/day): Guidelines strongly recommend avoiding dose escalation above 90 mg MME/day. Escalating beyond this ceiling provides diminishing analgesic returns while exponentially increasing overdose mortality, hyperalgesia, physical dependence, and endocrine disruption (hypogonadism, adrenal insufficiency).
• Discontinuation and Tapering: If an opioid trial fails to achieve clinically meaningful improvement in pain and function (defined as at least a 30% reduction in pain score and demonstrable functional improvement on validated tools like the Brief Pain Inventory), opioids should be systematically tapered and discontinued.

---

Opioid Adverse Effect Management

---

Transdermal Fentanyl Patches (Duragesic)

Transdermal fentanyl patches represent a potent, long-acting delivery system that requires strict adherence to safety guidelines:

                  TRANSDERMAL FENTANYL: CRITICAL SAFETY RULES

      OPIOID TOLERANCE THRESHOLD                   EXTERNAL HEAT BAN
┌──────────────────────────────────────┐     ┌──────────────────────────────────────┐
│ • STRICTLY FOR OPIOID-TOLERANT ONLY  │     │ • NO heating pads, hot tubs, saunas  │
│ • Minimum baseline for ≥ 7 days:     │     │ • Fever (> 39°C) accelerates release │
│   - Oral Morphine ≥ 60 mg/day        │     │ • Fatal toxicity can occur rapidly   │
│   - Oral Oxycodone ≥ 30 mg/day       │     │ • Terminal depot t1/2: 17–24 hours   │
│   - Oral Hydromorphone ≥ 8 mg/day    │     │ • Fold adhesive together for disposal│
└──────────────────────────────────────┘     └──────────────────────────────────────┘

1. Opioid Tolerance Requirement

Fentanyl patches are strictly contraindicated in acute pain, post-operative pain, mild pain, intermittent pain, or in opioid-naive patients. Under Health Canada labeling and clinical guidelines, a patient is defined as opioid-tolerant only if they have been taking, for at least 7 consecutive days, a minimum daily dose of:

• Oral Morphine: ≥ 60 mg daily; OR
• Oral Oxycodone: ≥ 30 mg daily; OR
• Oral Hydromorphone: ≥ 8 mg daily; OR
• An equianalgesic dose of another opioid.

2. Pharmacokinetics of Transdermal Absorption

• Fentanyl is highly lipophilic. Following initial patch application, fentanyl binds to epidermal and subcutaneous lipids, forming a subcutaneous depot before entering systemic capillaries.
• Onset of Analgesia: Delayed; requires 12 to 24 hours to achieve initial therapeutic plasma concentrations. Patients must continue their previous analgesic regimen for the first 12 to 18 hours after applying their first patch.
• Steady State: Achieved after 48 to 72 hours (after 2 consecutive patch applications).
• Duration of Delivery: Continuous delivery over 72 hours (changed every 3 days).
• Depot Elimination Half-Life: Upon patch removal, the subcutaneous depot continues to release fentanyl slowly into the circulation, resulting in a prolonged elimination half-life of 17 to 24 hours. Adverse effects (e.g., respiratory depression) cannot be reversed immediately by simply peeling off the patch; ongoing clinical observation and possible repeated naloxone dosing are necessary.

3. Thermal Acceleration & External Heat Hazards

• Mechanism: Heat increases cutaneous microvascular perfusion and enhances the permeability of the stratum corneum and patch membrane. Body temperatures of 40°C (104°F) can increase transdermal fentanyl absorption by over 30% to 50%, rapidly transforming a stable maintenance regimen into a lethal overdose.
• Patient Education: Patients and caregivers must never expose the patch application site to direct external heat sources, including electric heating pads, heat lamps, hot-water bottles, saunas, hot tubs, or heated waterbeds. Patients experiencing high systemic fevers (> 38.5°C to 39°C) must be closely monitored for fentanyl toxicity.

4. Application, Safe Removal, and Secure Disposal

• Apply to clean, dry, intact, non-hairy skin on the upper chest, back, flank, or upper arm. Clip hair if necessary (do not shave, as shaving abrades skin and accelerates absorption).
• Never alter, cut, or puncture a transdermal patch (cutting destroys the release membrane/matrix, risking dose dumping).
• To dispose of a used patch, fold the patch in half with the sticky adhesive surfaces pressed firmly together, place it in its original pouch, and return it to the pharmacy for destruction. Never flush patches or put them in household garbage where children or pets could find them. Some provinces run patch-for-patch return programs: Ontario, for example, requires used patches to be returned before new ones are dispensed.

---

Community Naloxone Distribution & Patient Education

Naloxone is a pure competitive mu-opioid receptor antagonist with high binding affinity. When administered to an opioid-toxic patient, it rapidly displaces opioid agonists from receptor sites, reversing central respiratory depression and restoring spontaneous ventilation within 2 to 5 minutes.

Core Candidates for Pharmacy Naloxone Co-Dispensing

Pharmacists should routinely offer and co-dispense a take-home naloxone kit to any patient who:

• Receives an opioid prescription with a total daily dose ≥ 50 mg MME/day;
• Is co-prescribed any benzodiazepine, sedative-hypnotic, gabapentinoid, or muscle relaxant alongside an opioid;
• Has chronic kidney disease, hepatic dysfunction, severe COPD, or obstructive sleep apnea;
• Has a personal history of substance use disorder, prior non-fatal overdose, or lives in a household with individuals at risk of accidental ingestion (e.g., young children, teenagers).

Patient and Caregiver Counselling on Overdose Response

1. Recognize the Toxidrome: Look for unresponsiveness to loud voice or firm sternal rub, shallow/absent respirations (< 8 breaths/min), snoring/gurgling ("death rattle"), cyanotic or grey nail beds and lips, and pinpoint pupils (miosis).
2. Call 911 Immediately: Naloxone temporary reversal lasts only 30 to 90 minutes, which is shorter than the half-life of most opioids (e.g., methadone, sustained-release oxycodone, transdermal fentanyl). As naloxone wears off, the patient will slip back into fatal respiratory arrest ("re-narcotization") unless advanced emergency care is on site.
3. Administer Naloxone:
   • Intramuscular (IM) Kit: Inject 0.4 mg (1 mL) into the anterolateral thigh or deltoid muscle.
   • Intranasal (IN) Spray: Spray 4 mg (one single-dose device) into one nostril.
4. Initiate Rescue Breathing & Re-dose: Provide chest compressions/rescue breathing. If the patient does not respond or spontaneous breathing is not restored within 2 to 3 minutes, administer a second dose of naloxone in the alternate thigh or nostril.

---

Clinical Case Scenario: Comprehensive Opioid Rotation & Stewardship

A 68-year-old male with chronic lumbar radicular pain and severe osteoarthritic knee pain presents to the dispensary. He has been taking oral oxycodone controlled-release (CR) 40 mg PO Q12H, supplemented with oral oxycodone immediate-release (IR) 10 mg PO PRN, averaging 3 breakthrough tablets daily for the past 6 months (total daily oxycodone = 80 mg CR + 30 mg IR = 110 mg/day). He reports that despite this regimen, his pain score remains 7/10, he is troubled by intolerable daytime grogginess and severe constipation (bowel movement once every 5 days), and his mobility has deteriorated. His physician wishes to rotate him to oral hydromorphone sustained-release (SR).

Pharmacist Clinical Calculation & Care Plan:

1. Calculate Baseline Daily Dose and MME: $\text{Total 24-hour Oxycodone Dose} = 80\text{ mg} + 30\text{ mg} = 110\text{ mg/day}$ $\text{Total Daily MME} = 110\text{ mg} \times 1.5 = 165\text{ mg MME/day}$ Note: This exceeds both the 50 mg watchful threshold and the 90 mg upper ceiling of the Canadian Opioid Guideline.
2. Convert to Equianalgesic Oral Hydromorphone: $\text{Equianalgesic Hydromorphone Dose} = \frac{165\text{ mg MME}}{5.0} = 33\text{ mg/day of oral hydromorphone}$
3. Apply a 30% Dose Reduction for Incomplete Cross-Tolerance: $\text{Reduced Daily Target} = 33\text{ mg} \times (1 - 0.30) = 33\text{ mg} \times 0.70 = 23.1\text{ mg/day}$
4. Design New Regimen:
   • Regular Formulation: Hydromorphone SR 12 mg PO Q12H (total regular dose = 24 mg/day).
   • Breakthrough PRN: Hydromorphone IR 2 mg PO every 4 hours PRN pain (approximately 10% of total daily dose).
5. Bowel Regimen Optimization: Discontinue PRN docusate. Initiate scheduled senna 1 to 2 tablets PO BID plus polyethylene glycol (PEG 3350) 17 g dissolved in water PO once daily.
6. Harm Reduction Co-Dispensing: Provide an intranasal take-home naloxone kit (4 mg) and train the patient and his spouse on overdose recognition and emergency 911 dispatch.